In the span of just a few short months, the ramifications and impact of COVID-19 have been vast. Virtually every aspect of public health has been affected by this pandemic, and the fight against antibiotic-resistant bacteria is no exception.
As of December 2019, an estimated 30 new nontraditional products with the potential to treat or prevent serious bacterial infections were in clinical development. Below is a snapshot of the current nontraditional products pipeline, based on publicly available information and informed by external experts.
Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.